Viridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Holdings Lifted by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 6.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 516,213 shares of the company’s stock after acquiring an additional 32,292 shares during the period. Charles Schwab Investment Management Inc. owned about 0.81% of Viridian Therapeutics worth $11,744,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of VRDN. Quest Partners LLC increased its position in shares of Viridian Therapeutics by 344.0% in the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after acquiring an additional 4,692 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after purchasing an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC grew its holdings in shares of Viridian Therapeutics by 108.3% during the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock valued at $163,000 after buying an additional 6,500 shares in the last quarter. Arizona State Retirement System raised its position in Viridian Therapeutics by 14.7% during the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after buying an additional 1,688 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Viridian Therapeutics in the 3rd quarter worth about $208,000.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $19.72 on Monday. Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The stock’s 50-day moving average is $22.53 and its two-hundred day moving average is $17.65. The firm has a market cap of $1.56 billion, a P/E ratio of -4.58 and a beta of 1.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Stephen F. Mahoney acquired 21,400 shares of the stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the purchase, the chief executive officer now owns 21,400 shares in the company, valued at approximately $499,262. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Thomas W. Beetham acquired 5,000 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the acquisition, the chief operating officer now owns 6,000 shares in the company, valued at approximately $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 1,626,400 shares of company stock valued at $30,616,312 over the last 90 days. 0.65% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 target price on shares of Viridian Therapeutics in a research note on Thursday. HC Wainwright upped their price objective on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. TD Cowen began coverage on shares of Viridian Therapeutics in a research note on Monday, November 25th. They set a “buy” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research note on Monday, November 25th. Finally, The Goldman Sachs Group increased their price objective on Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $36.33.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.